In 2019, AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) launched a five-year research collaboration, The Biopharma Collaborative (BPC), with a coalition of ten biopharmaceutical companies with the goal of obtaining clinical and genomic data from an estimated 50,000 de-identified patients treated at the institutions participating in AACR Project GENIE. The additional clinical data collected as part of the BPC furthers the goals of advancing precision oncology and powering clinical decision-making through open and transparent data sharing.

See our biopharmaceutical collaborators.

In the first two years, Phase 1, the project added prior cancer treatments, tumor pathology, and clinical outcomes to the clinical data already linked with the genomic profiles of nearly 8,000 bladder, breast, colorectal, lung, pancreatic, and prostate cancer patients treated at Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Princess Margaret Cancer Center, and Vanderbilt-Ingram Cancer Center. In years three through five, Phase 2, data collection will be expanded to additional cancer types from additional participating institutions. 

Real-world genomic and clinical data available

• 1,846 non-small cell lung cancer (NSCLC) patients
• 1,485 colorectal patients
• An R package for analyzing these data is available here and here.
• Read about how to use the package.

To view members of this team, visit our page, the 2022 BPC Core Team.